Imiquimod intravesicular

Drug Profile

Imiquimod intravesicular

Alternative Names: TMX-101; Vesimune

Latest Information Update: 19 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Telormedix
  • Class Adjuvants; Aminoquinolines; Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bladder cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 13 Jan 2016 UroGen Pharma acquires imiquimod intravesicular from Telormedix
  • 29 Sep 2015 No recent reports on development identified - Phase-I/II for Bladder cancer (Adjuvant therapy) in Germany and Netherlands (Intravesicular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top